136 related articles for article (PubMed ID: 26275176)
1. Brief Report: Doubly Robust Estimation of Standardized Risk Difference and Ratio in the Exposed Population.
Shinozaki T; Matsuyama Y
Epidemiology; 2015 Nov; 26(6):873-7. PubMed ID: 26275176
[TBL] [Abstract][Full Text] [Related]
2. Marginal structural models as a tool for standardization.
Sato T; Matsuyama Y
Epidemiology; 2003 Nov; 14(6):680-6. PubMed ID: 14569183
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
[TBL] [Abstract][Full Text] [Related]
4. Use of tamoxifen in pT1a-pT1b, pN0 breast cancer.
Livi L; Saieva C; Paiar F; Simontacchi G; Galardi A; De Luca Cardillo C; Mangoni M; Paoletti L; Ponticelli P; Biti GP
Eur J Surg Oncol; 2007 Apr; 33(3):271-5. PubMed ID: 16831531
[TBL] [Abstract][Full Text] [Related]
5. Doubly robust estimators of causal exposure effects with missing data in the outcome, exposure or a confounder.
Williamson EJ; Forbes A; Wolfe R
Stat Med; 2012 Dec; 31(30):4382-400. PubMed ID: 23086504
[TBL] [Abstract][Full Text] [Related]
6. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
Lash TL; Gurwitz JH; Silliman RA
J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
[TBL] [Abstract][Full Text] [Related]
7. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
8. Impact of outcome model misspecification on regression and doubly-robust inverse probability weighting to estimate causal effect.
Lefebvre G; Gustafson P
Int J Biostat; 2010; 6(2):Article 15. PubMed ID: 21969999
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
10. Smaller reduction in 3D breast density associated with subsequent cancer recurrence in patients with breast cancer receiving adjuvant tamoxifen therapy.
Kim JY; Cho N; Jeyanth JX; Kim WH; Lee SH; Gweon HM; Moon WK
AJR Am J Roentgenol; 2014 Apr; 202(4):912-21. PubMed ID: 24660724
[TBL] [Abstract][Full Text] [Related]
11. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
12. Inverse probability weighting and doubly robust standardization in the relative survival framework.
Syriopoulou E; Rutherford MJ; Lambert PC
Stat Med; 2021 Nov; 40(27):6069-6092. PubMed ID: 34523751
[TBL] [Abstract][Full Text] [Related]
13. Primary tumor and patient characteristics in breast cancer as predictors of adjuvant therapy regimen: a regression model.
Francescutti V; Farrokhyar F; Tozer R; Heller B; Lovrics P; Jansz G; Kahnamoui K
Cancer Chemother Pharmacol; 2011 Sep; 68(3):661-8. PubMed ID: 21125276
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing loco-regional relapse in older breast cancer patients treated with tumour resection and tamoxifen.
Kontos M; Allen DS; Agbaje OF; Hamed H; Fentiman IS
Eur J Surg Oncol; 2011 Dec; 37(12):1051-8. PubMed ID: 21843919
[TBL] [Abstract][Full Text] [Related]
15. Doubly robust estimation of causal effects.
Funk MJ; Westreich D; Wiesen C; Stürmer T; Brookhart MA; Davidian M
Am J Epidemiol; 2011 Apr; 173(7):761-7. PubMed ID: 21385832
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
17. MnSOD rs4880 and XPD rs13181 polymorphisms predict the survival of breast cancer patients treated with adjuvant tamoxifen.
Tengström M; Mannermaa A; Kosma VM; Soini Y; Hirvonen A; Kataja V
Acta Oncol; 2014 Jun; 53(6):769-75. PubMed ID: 24716840
[TBL] [Abstract][Full Text] [Related]
18. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ejlertsen B; Jensen MB; Mouridsen HT;
Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of adjuvant tamoxifen therapy among older women with early stage breast cancer.
Owusu C; Lash TL; Silliman RA
Breast J; 2007; 13(4):374-82. PubMed ID: 17593042
[TBL] [Abstract][Full Text] [Related]
20. Model misspecification and robustness in causal inference: comparing matching with doubly robust estimation.
Waernbaum I
Stat Med; 2012 Jul; 31(15):1572-81. PubMed ID: 22359267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
